Mambalgin-1 vs Kahalalide F
Head-to-head comparison of Mambalgin-1 (Mambalgin-1 from Dendroaspis polylepis venom) and Kahalalide F (Kahalalide F) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Mambalgin-1 | Kahalalide F |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Mambalgin-1 from Dendroaspis polylepis venom | Kahalalide F |
| Molecular Weight | 6,300 Da | 1111.3 Da |
| Half-Life | Minutes to hours | N/A |
| Amino Acids | 57 | N/A |
| Typical Dose | 0.1-1 nmol intrathecal|10-100 nM in vitro|single-dose rodent studies | 0.1-3 mg/m2 IV in early trials |
| Route | Intrathecal | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 55 | 85 |
| Research Status | Pre-clinical | Pre-clinical |
Mambalgin-1 Benefits
- ✓ASIC channel inhibition
- ✓non-opioid analgesia research
- ✓sensory-neuron physiology
- ✓lead optimization for pain therapeutics
Kahalalide F Benefits
- ✓antineoplastic
- ✓pro-apoptotic
- ✓membrane-active
- ✓anti-proliferative
Mambalgin-1 Dosing
Intrathecal pain-behavior studies|ASIC1a/ASIC1b electrophysiology|Acute dosing in rodents
Kahalalide F Dosing
IV infusion in phase I oncology studies|dose escalation used in trials|preclinical nanomolar assays
Mambalgin-1 Side Effects
- ⚠Hypoactivity at high dose
- ⚠off-target ASIC blockade
- ⚠local irritation
Kahalalide F Side Effects
- ⚠fatigue
- ⚠nausea
- ⚠transaminase elevation
Research Overview
Mambalgin-1
Pre-clinical work shows mambalgin-1 can reduce pain behaviors by modulating proton-gated ion channels in peripheral and central pathways. It has become an important template for developing ASIC-targeted analgesics.
Kahalalide F
Kahalalide F was investigated in multiple preclinical and early clinical cancer studies because of its unusual membrane-disrupting and anti-tumor effects. Development highlighted the promise and limits of marine depsipeptides as oncology leads.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.